
  
    
      
        Background_NNP
        The_DT cytokine_NN interleukin-_NN 2_CD (_( IL-_NNP 2_LS )_) has_VBZ been_VBN used_VBN
        extensively_RB as_IN a_DT single_JJ agent_NN for_IN immune_JJ modulation_NN of_IN the_DT
        host_NN in_IN cancer_NN therapy_NN [_NN 1_CD ,_, 2_CD ]_NN ._. Clinical_NNP regression_NN of_IN
        metastatic_JJ melanoma_NN and_CC renal_JJ cell_NN cancer_NN resulted_VBD in_IN
        long-term_JJ cures_NNS ,_, and_CC IL-_NNP 2_CD has_VBZ been_VBN approved_VBN by_IN the_DT Food_NNP and_CC
        Drug_NNP Administration_NNP for_IN standard_JJ therapy_NN ._. Systemic_NNP IL-_NNP 2_CD
        administration_NN also_RB appears_VBZ to_TO dramatically_RB increase_VB the_DT
        frequency_NN of_IN tumor_NN regression_NN in_IN specific_JJ immunization_NN
        against_IN cancer_NN [_NN 3_CD ]_NN ._. It_PRP has_VBZ been_VBN postulated_JJ on_IN clinical_JJ
        grounds_NNS that_IN the_DT anti-cancer_JJ effects_NNS of_IN IL-_NNP 2_CD are_VBP mediated_JJ
        through_IN 
        in_IN vivo_NN expansion_NN and_CC activation_NN of_IN
        cytotoxic_JJ lymphocytes_NNS [_NN 1_CD ]_NN and_CC /_NN or_CC promotion_NN of_IN their_PRP$
        migration_NN within_IN target_NN tissues_NNS [_NN 3_CD ]_NN ,_, but_CC it_PRP has_VBZ become_VBN
        apparent_JJ that_IN IL-_NNP 2_CD at_IN the_DT doses_NNS used_VBN therapeutically_RB has_VBZ
        broader_JJR immune_JJ /_NN pro-inflammatory_JJ effects_NNS [_NN 4_CD ,_, 5_CD ]_NN ._. In_IN
        addition_NN ,_, IL-_NNP 2_CD may_MD have_VB a_DT role_NN in_IN activation-induced_JJ T-_NNP cell_NN
        death_NN ,_, therefore_RB causing_VBG peripheral_JJ tolerance_NN [_NN 6_CD ,_, 7_CD ]_NN ._. IL-_NNP 2_CD
        administration_NN is_VBZ also_RB associated_VBN with_IN potent_JJ systemic_JJ
        toxicity_NN that_IN limits_VBZ its_PRP$ therapeutic_JJ usefulness_NN [_NN 8_CD ]_NN ,_, and_CC a_DT
        relationship_NN between_IN toxicity_NN and_CC clinical_JJ effectiveness_NN
        has_VBZ been_VBN observed_VBN ,_, suggesting_VBG a_DT common_JJ effector_NN pathway_NN [_NN
        9_CD ]_NN ._. Most_JJS peculiarly_RB ,_, the_DT extent_NN of_IN IL-_NNP 2_CD -_: induced_VBN
        thrombocytopenia_NN and_CC lymphopenia_NN is_VBZ associated_VBN with_IN
        increased_VBN frequency_NN of_IN clinical_JJ responses_NNS [_NN 10_CD ]_NN ._. Reversal_NNP
        of_IN IL-_NNP 2_CD -_: induced_VBN toxicity_NN by_IN corticosteroid_NN or_CC anti-tumor_JJ
        necrosis_NNS factor-α_JJ (_( TNF-α_NNP )_) antibodies_NNS also_RB blunts_NNS its_PRP$
        therapeutic_JJ efficacy_NN ,_, further_JJ indicating_VBG the_DT mandatory_JJ
        nature_NN of_IN this_DT association_NN [_NN 11_CD ,_, 12_CD ]_NN ._. The_DT ability_NN to_TO
        distinguish_VB the_DT effects_NNS of_IN IL-_NNP 2_CD in_IN target_NN tissues_NNS from_IN its_PRP$
        systemic_JJ effects_NNS may_MD yield_VB important_JJ insights_NNS for_IN the_DT
        development_NN of_IN improved_VBN anti-cancer_JJ therapies_NNS ._.
        With_IN the_DT advent_NN of_IN functional_JJ genomics_NNS [_NN 13_CD ]_NN ,_, it_PRP has_VBZ
        become_VBN possible_JJ to_TO study_VB complex_JJ biological_JJ behaviors_NNS in_IN
        concert_NN in_IN order_NN to_TO obtain_VB a_DT panoramic_JJ view_NN of_IN downstream_JJ
        events_NNS resulting_VBG from_IN pathophysiological_JJ alterations_NNS of_IN
        entire_JJ biosystems_NNS ._. Thus_RB ,_, various_JJ aspects_NNS of_IN the_DT immune_JJ
        response_NN can_MD be_VB analyzed_VBN 
        in_IN vitro_NN [_NN 14_CD ]_NN ._. To_TO our_PRP$ knowledge_NN ,_,
        however_RB ,_, little_JJ information_NN is_VBZ available_JJ about_IN the_DT effects_NNS
        of_IN IL-_NNP 2_CD in_IN controlled_VBN 
        in_IN vitro_NN conditions_NNS [_NN 15_CD ]_NN and_CC none_NN
        about_IN the_DT effects_NNS of_IN 
        in_IN vivo_NN administration_NN ._. We_PRP have_VBP
        therefore_RB characterized_VBN the_DT effects_NNS of_IN IL-_NNP 2_CD administration_NN 
        in_IN vivo_NN on_IN the_DT transcriptional_NN
        program_NN of_IN circulating_VBG cells_NNS as_IN markers_NNS of_IN its_PRP$ systemic_JJ
        effect_NN ,_, and_CC on_IN the_DT tumor_NN microenvironment_NN as_IN a_DT marker_NN of_IN
        its_PRP$ effect_NN on_IN target_NN tissue_NN ._.
        We_PRP compared_VBD the_DT time_NN course_NN of_IN gene_NN induction_NN after_IN 
        in_IN vitro_NN exposure_NN of_IN peripheral_JJ blood_NN
        mononuclear_NN cells_NNS (_( PBMC_NNP )_) to_TO IL-_NNP 2_CD (_( 6_CD ,_, 000_CD IU_NNP /_NN ml_NN )_) with_IN 
        in_IN vivo_NN exposure_NN to_TO a_DT dose_NN regimen_NN
        (_( 720_CD ,_, 000_CD IU_NNP /_NN kg_NN every_DT 8_CD hours_NNS )_) ,_, which_WDT is_VBZ associated_VBN with_IN
        fairly_RB high_JJ systemic_JJ toxicity_NN and_CC clinical_JJ effectiveness_NN [_NN
        16_CD ]_NN ._. The_DT changes_NNS in_IN expression_NN profile_NN induced_VBN by_IN IL-_NNP 2_CD in_IN
        the_DT tumor_NN microenvironment_NN were_VBD monitored_VBN by_IN repeated_VBN
        fine-needle_JJ aspiration_NN (_( FNA_NNP )_) biopsies_NNS ._. Amplified_NNP antisense_NN
        RNA_NNP (_( aRNA_NN )_) obtained_VBN from_IN 
        in_IN vitro_NN or_CC 
        ex_FW vivo_NN samples_NNS was_VBD fluorescence_NN
        labeled_VBN and_CC hybridized_JJ to_TO 6_CD ,_, 500_CD -_: spot_NN cDNA_NN arrays_NNS as_RB
        previously_RB described_VBD [_NN 17_CD ]_NN ._.
        Test_NN samples_NNS consisted_VBD of_IN gradient-separated_JJ PBMC_NNP
        exposed_VBD either_CC 
        in_IN vitro_NN or_CC 
        in_IN vivo_NN to_TO IL-_NNP 2_CD ,_, labeled_VBN with_IN Cy_NNP 5_CD
        (_( red_JJ )_) and_CC co-hybridized_JJ with_IN reference_NN samples_NNS labeled_VBN with_IN
        Cy_NNP 3_CD (_( green_JJ )_) ._. Reference_NNP samples_NNS for_IN PBMC_NNP consisted_VBD of_IN
        corresponding_JJ material_NN for_IN each_DT experiment_NN obtained_VBN before_IN
        IL-_NNP 2_CD exposure_NN ._. For_IN 
        in_IN vitro_NN experiments_NNS ,_, for_IN example_NN ,_,
        reference_NN samples_NNS were_VBD PBMC_NNP cultured_JJ in_IN the_DT absence_NN of_IN
        IL-_NNP 2_CD ._. For_IN 
        ex_FW vivo_NN experiments_NNS ,_, references_NNS
        consisted_VBD of_IN PBMC_NNP obtained_VBD from_IN the_DT respective_JJ patient_NN
        before_IN IL-_NNP 2_CD administration_NN ._. For_IN test_NN FNA_NNP samples_NNS obtained_VBN
        during_IN the_DT course_NN of_IN IL-_NNP 2_CD administration_NN ,_, reference_NN
        material_NN consisted_VBD of_IN FNA_NNP from_IN the_DT respective_JJ lesion_NN
        obtained_VBN before_IN IL-_NNP 2_CD therapy_NN ._. This_DT unusual_JJ strategy_NN was_VBD
        selected_VBN to_TO emphasize_VB the_DT differences_NNS between_IN pre-_NN and_CC
        post-_NN IL-_NNP 2_CD -_: exposure_NN expression_NN profiles_NNS while_IN minimizing_VBG
        differences_NNS related_VBN to_TO individual_JJ lesion_NN and_CC /_NN or_CC patient_NN
        heterogeneity_NN ._. The_DT complete_JJ data_NN set_VBN was_VBD filtered_VBN ,_, letting_VBG
        through_IN only_JJ genes_NNS expressed_VBD at_IN ratios_NNS >_NN 3_CD or_CC <_NN 0_CD ._. 33_CD
        compared_VBN to_TO the_DT reference_NN in_IN at_IN least_JJS one_CD experiment_NN ._. A_DT
        parameter_NN was_VBD applied_VBN to_TO the_DT filter_NN that_WDT selected_VBD genes_NNS
        whose_WP$ fluorescence_NN intensity_NN was_VBD above_IN 300_CD in_IN one_CD channel_NN
        at_IN least_JJS in_IN one_CD experiment_NN ._. This_DT arbitrary_JJ threshold_NN was_VBD
        chosen_VBN to_TO exclude_VB genes_NNS whose_WP$ fluorescence_NN intensity_NN was_VBD
        close_RB to_TO background_NN fluorescence_NN ._. To_TO recover_VB possibly_RB
        useful_JJ information_NN ,_, this_DT filter_NN was_VBD removed_VBN if_IN the_DT same_JJ
        gene_NN demonstrated_VBD high_JJ intensity_NN of_IN fluorescence_NN in_IN the_DT
        other_JJ channel_NN (_( >_NN 3_CD ,_, 000_CD )_) in_IN at_IN least_JJS one_CD experiment_NN ._. A_DT
        total_NN of_IN 2_CD ,_, 393_CD genes_NNS out_IN of_IN the_DT 6_CD ,_, 500_CD clones_NNS were_VBD selected_VBN
        for_IN subsequent_JJ analyses_NNS ._.
      
      
        Results_NNS
        
          Technical_JJ challenges_NNS
          Administration_NNP of_IN IL-_NNP 2_CD in_IN humans_NNS induces_VBZ dramatic_JJ
          changes_NNS in_IN the_DT frequency_NN of_IN different_JJ subsets_NNS of_IN
          circulating_VBG cells_NNS ._. These_DT changes_NNS need_VBP to_TO be_VB addressed_VBN
          when_WRB considering_VBG the_DT more_RBR specific_NN and_CC minute_NN changes_NNS
          induced_VBN at_IN the_DT transcriptional_NN level_NN by_IN this_DT cytokine_NN ._.
          Perhaps_RB the_DT most_RBS perplexing_JJ effect_NN of_IN IL-_NNP 2_CD administration_NN
          is_VBZ a_DT rapid_JJ (_( within_IN 1_CD hour_NN )_) and_CC paradoxical_JJ clearance_NN of_IN
          monocytes_NNS and_CC lymphocytes_NNS from_IN the_DT peripheral_JJ blood_NN
          (_( Figure_NN 1_CD a_DT )_) ._. IL-_NNP 2_CD may_MD directly_RB eliminate_VB mononuclear_NN
          cells_NNS through_IN activation-induced_JJ death_NN [_NN 6_CD ,_, 7_CD ]_NN ._. Contrary_JJ
          to_TO the_DT 
          in_IN vivo_NN observation_NN ,_, however_RB ,_, 
          in_IN vitro_NN stimulation_NN with_IN IL-_NNP 2_CD
          (_( 6_CD ,_, 000_CD IU_NNP /_NN ml_NN )_) of_IN PBMC_NNP obtained_VBD from_IN apheresis_NNS of_IN melanoma_NN
          patients_NNS did_VBD not_RB alter_VB mononuclear_NN cell_NN counts_VBZ ,_,
          suggesting_VBG that_DT cell_NN death_NN is_VBZ not_RB a_DT direct_JJ effect_NN of_IN IL-_NNP 2_CD
          (_( Figure_NN 1_CD b_SYM )_) ._. A_DT substantial_JJ difference_NN between_IN
          gradient-separated_JJ PBMC_NNP and_CC circulating_VBG cells_NNS 
          in_IN vivo_NN is_VBZ the_DT lack_NN of_IN plasma_NN ,_,
          platelets_NNS and_CC polymorphonuclear_NN cells_NNS as_IN a_DT result_NN of_IN the_DT
          apheresis_NNS process_VBP ._. This_DT may_MD directly_RB or_CC indirectly_RB
          contribute_VB to_TO mononuclear_NN cell_NN death_NN 
          in_IN vivo_NN in_IN response_NN to_TO IL-_NNP 2_CD
          administration_NN ._. However_RB ,_, IL-_NNP 2_CD (_( 6_CD ,_, 000_CD lU_NN /_NN ml_NN )_) stimulation_NN
          of_IN lepirudin-treated_JJ (_( Aventis_NNP Pharmaceuticals_NNP ,_, Kansas_NNP
          City_NNP ,_, MO_NNP )_) fresh_JJ blood_NN did_VBD not_RB alter_VB mononuclear_NN cell_NN
          number_NN (_( data_NNS not_RB shown_VBN )_) ,_, suggesting_VBG a_DT limited_JJ role_NN for_IN
          lymphocyte_NN apoptosis_NNS as_IN the_DT cause_NN of_IN their_PRP$ rapid_JJ
          clearance_NN from_IN the_DT circulation_NN ._.
          Whatever_WDT the_DT reason_NN ,_, the_DT dramatic_JJ changes_NNS in_IN the_DT
          proportions_NNS of_IN different_JJ subsets_NNS of_IN circulating_VBG cells_NNS
          during_IN IL-_NNP 2_CD therapy_NN introduce_VB a_DT strong_JJ bias_NN into_IN the_DT
          interpretation_NN of_IN the_DT 
          in_IN vivo_NN data_NNS ._. Observed_NNP variations_NNS
          in_IN gene-expression_JJ profile_NN could_MD be_VB due_JJ to_TO differential_NN
          gene_NN expression_NN in_IN individual_JJ cells_NNS ,_, shifting_VBG proportions_NNS
          of_IN different_JJ cell_NN subsets_NNS ,_, or_CC a_DT combination_NN of_IN the_DT two_CD ._.
          The_DT effect_NN of_IN proportional_JJ shifts_NNS in_IN cell_NN subsets_NNS could_MD
          not_RB be_VB overcome_VBN by_IN 
          ex_FW vivo_NN mechanical_JJ separation_NN of_IN
          these_DT subsets_NNS because_IN of_IN the_DT limited_JJ quantity_NN of_IN material_NN
          obtained_VBN from_IN blood_NN draws_VBZ (_( 20_CD ml_NN )_) ._. However_RB ,_, density_NN
          gradient_NN separation_NN of_IN PBMC_NNP almost_RB totally_RB compensated_VBN
          for_IN these_DT shifts_NNS by_IN eliminating_VBG polymorphonuclear_NN cells_NNS ,_,
          eosinophils_NNS and_CC basophils_NNS (_( Figure_NN 1_CD c_SYM )_) ,_, and_CC leaving_VBG a_DT
          mononuclear_NN cell_NN population_NN comparable_JJ with_IN pre-_NN IL-_NNP 2_CD
          treatment_NN samples_NNS ._. (_( PBMC_NNP from_IN apheresis_NNS used_VBN as_IN reference_NN
          for_IN 
          in_IN vivo_NN studies_NNS and_CC as_IN source_NN of_IN
          cells_NNS for_IN 
          in_IN vitro_NN studies_NNS are_VBP highly_RB
          enriched_JJ in_IN monocytes_NNS and_CC lymphocytes_NNS ,_, as_IN seen_VBN in_IN Figure_NN
          1_CD b_SYM ._. )_) Therefore_RB ,_, both_DT 
          in_IN vivo_NN and_CC 
          in_IN vitro_NN studies_NNS reflected_VBD similar_JJ
          starting_NN populations_NNS of_IN mononuclear_NN cells_NNS ._. This_DT ,_, at_IN least_JJS
          in_IN part_NN ,_, mitigated_JJ the_DT variation_NN in_IN gene-profile_JJ pattern_NN
          due_JJ to_TO shifting_VBG cell-subset_JJ proportions_NNS 
          in_IN vivo_NN ._. 
          It_PRP has_VBZ been_VBN suggested_VBN that_IN rapid_JJ clearance_NN of_IN
          mononuclear_NN cells_NNS after_IN IL-_NNP 2_CD administration_NN is_VBZ due_JJ to_TO
          increased_VBN permeability_NN of_IN vascular_NN endothelium_NN [_NN 4_CD ]_NN ,_,
          facilitating_VBG cell_NN migration_NN into_IN extravascular_NN spaces_NNS
          including_VBG tumor_NN sites_NNS [_NN 3_CD ]_NN ._. However_RB ,_, the_DT level_NN of_IN genes_NNS
          constitutively_RB expressed_VBN by_IN various_JJ subsets_NNS of_IN
          mononuclear_NN cells_NNS did_VBD not_RB change_VB significantly_RB within_IN the_DT
          tumor_NN microenvironment_NN ._. Differential_NNP display_NN of_IN
          pre-compared_JJ with_IN post-_NN IL-_NNP 2_CD specimens_NNS detected_VBD changes_NNS
          only_RB in_IN circulating_VBG cells_NNS (_( that_WDT is_VBZ ,_, of_IN genes_NNS for_IN CD_NNP 8_CD ,_,
          CD_NNP 3_CD ,_, CD_NNP 10_CD and_CC CD_NNP 24_CD ;_: green_JJ and_CC gray_JJ bars_NNS in_IN Figure_NN 1_CD d_SYM )_) ._.
          These_DT most_RBS probably_RB reflected_VBD proportional_JJ shifts_NNS in_IN cell_NN
          subsets_NNS rather_RB than_IN altered_VBN gene_NN expression_NN ,_, because_IN the_DT
          level_NN of_IN expression_NN of_IN the_DT same_JJ genes_NNS remained_VBD constant_JJ
          in_IN the_DT 
          in_IN vitro_NN time_NN course_NN (_( data_NNS not_RB
          shown_VBN )_) ._. No_DT changes_NNS could_MD be_VB detected_VBN in_IN FNAs_NNP obtained_VBD
          pre-_NN IL-_NNP 2_CD administration_NN compared_VBN with_IN FNAs_NNP obtained_VBD 3_CD
          hours_NNS after_IN one_CD (_( light-blue_JJ bar_NN )_) or_CC four_CD (_( dark-blue_JJ bar_NN )_)
          doses_NNS ._. We_PRP could_MD not_RB confirm_VB the_DT aRNA-based_JJ results_NNS by_IN
          immunohistochemistry_NN because_IN the_DT material_NN obtainable_JJ by_IN
          FNA_NNP was_VBD not_RB sufficient_JJ for_IN both_DT analyses_NNS ._. However_RB ,_, we_PRP
          have_VBP previously_RB shown_VBN good_JJ correlation_NN between_IN transcript_NN
          detection_NN of_IN cellular_JJ markers_NNS in_IN aRNA_NN ,_, total_JJ RNA_NNP and_CC at_IN
          the_DT protein_NN level_NN [_NN 18_CD ]_NN ._.
          We_PRP further_RBR evaluated_VBD the_DT effects_NNS of_IN IL-_NNP 2_CD on_IN
          endothelial_NN cell_NN permeability_NN as_IN a_DT possible_JJ factor_NN
          mediating_VBG migration_NN of_IN circulating_VBG immune_JJ cells_NNS into_IN the_DT
          tumor_NN site_NN ._. IL-_NNP 2_CD had_VBD no_DT direct_JJ impact_NN on_IN the_DT permeability_NN
          of_IN human_JJ umbilical_JJ vein_NN endothelial_NN cells_NNS (_( HUVEC_NNP )_) (_( Figure_NN
          1_CD e_SYM )_) ._. The_DT addition_NN of_IN PBMC_NNP enriched_JJ in_IN lymphocytes_NNS and_CC
          monocytes_NNS by_IN gradient_NN separation_NN increased_VBD the_DT
          permeability_NN of_IN HUVEC_NNP within_IN 3_CD hours_NNS ._. Treatment_NNP of_IN the_DT
          enriched_JJ PBMC_NNP with_IN IL-_NNP 2_CD (_( 6_CD ,_, 000_CD IU_NNP /_NN ml_NN )_) increased_VBN HUVEC_NNP
          permeability_NN (_( compared_VBN to_TO PBMC_NNP alone_RB )_) only_RB after_IN 24_CD hours_NNS
          (_( Student_NNP 
          t_NN -_: test_NN 
          p_NN =_SYM 0_CD ._. 02_CD )_) ._. This_DT finding_VBG suggests_VBZ
          that_IN IL-_NNP 2_CD affects_VBZ endothelial_NN cell_NN permeability_NN through_IN
          activation_NN of_IN PBMC_NNP ._. The_DT delayed_VBN effect_NN of_IN IL-_NNP 2_CD on_IN
          endothelial_NN cell_NN permeability_NN observed_VBD with_IN this_DT
          functional_JJ assay_NN was_VBD supported_VBN by_IN gene_NN profiling_VBG ._. IL-_NNP 2_CD
          alone_RB had_VBD minimal_JJ effects_NNS on_IN HUVEC_NNP ._. Supernatant_NNP from_IN PBMC_NNP
          cultures_NNS in_IN serum-free_JJ medium_NN had_VBD extensive_JJ effects_NNS on_IN
          HUVEC_NNP transcriptional_NN profile_NN (_( data_NNS not_RB shown_VBN )_) ._. However_RB ,_,
          supernatants_NNS from_IN PBMC_NNP conditioned_VBN for_IN 24_CD hours_NNS with_IN IL-_NNP 2_CD
          (_( 6_CD ,_, 000_CD IU_NNP /_NN ml_NN )_) induced_VBN differential_NN expression_NN in_IN six_CD
          additional_JJ groups_NNS of_IN genes_NNS (_( Figure_NN 1_CD f_SYM )_) that_WDT could_MD not_RB be_VB
          induced_VBN with_IN supernatants_NNS conditioned_VBN for_IN 3_CD hours_NNS ._. These_DT
          results_NNS suggest_VBP that_IN the_DT effect_NN of_IN IL-_NNP 2_CD on_IN endothelial_NN
          cells_NNS is_VBZ predominantly_RB mediated_JJ indirectly_RB ,_, through_IN
          activation_NN of_IN immune_JJ cells_NNS ,_, and_CC occurs_VBZ at_IN a_DT later_JJ stage_NN
          of_IN IL-_NNP 2_CD treatment_NN ._. This_DT conclusion_NN is_VBZ in_IN line_NN with_IN the_DT
          clinical_JJ observation_NN that_IN fluid_JJ shifts_NNS and_CC vascular_NN leak_NN
          occur_VB in_IN the_DT later_JJ phases_NNS of_IN high-dose_JJ IL-_NNP 2_CD therapy_NN ._.
          Taken_VBN together_RB ,_, these_DT results_NNS suggest_VBP that_IN immediate_JJ
          migration_NN of_IN mononuclear_NN cells_NNS to_TO the_DT tumor_NN
          microenvironment_NN is_VBZ not_RB the_DT primary_JJ effector_NN mechanism_NN of_IN
          systemic_JJ IL-_NNP 2_CD administration_NN ._. This_DT observation_NN ,_, of_IN
          course_NN ,_, does_VBZ not_RB exclude_VB the_DT possibility_NN that_IN ,_, at_IN a_DT later_JJ
          time_NN ,_, mononuclear_NN cells_NNS might_MD migrate_VB or_CC proliferate_VBP at_IN
          the_DT tumor_NN site_NN ._. The_DT reason_NN for_IN the_DT clearance_NN of_IN
          circulating_VBG cells_NNS immediately_RB following_VBG IL-_NNP 2_CD
          administration_NN remains_VBZ unsolved_JJ ,_, and_CC may_MD be_VB related_VBN to_TO
          their_PRP$ sequestration_NN in_IN the_DT reticular_NN endothelial_NN system_NN ,_,
          a_DT hypothesis_NNS that_WDT could_MD not_RB be_VB evaluated_VBN by_IN this_DT
          study_NN ._.
        
        
          Time-course_NNP analysis_NN of_IN IL-_NNP 2_CD -_: induced_VBN gene_NN
          expression_NN in_IN PBMC_NNP in_IN vitro_NN
          To_TO assess_VB the_DT direct_JJ effect_NN of_IN IL-_NNP 2_CD on_IN mononuclear_NN
          cells_NNS without_IN the_DT experimental_JJ noise_NN caused_VBN by_IN
          proportional_JJ shifts_NNS in_IN cell_NN subsets_NNS ,_, we_PRP first_RB determined_VBD
          the_DT transcriptional_NN changes_NNS occurring_VBG on_IN exposure_NN of_IN PBMC_NNP
          to_TO IL-_NNP 2_CD 
          in_IN vitro_NN ._. IL-_NNP 2_CD has_VBZ direct_JJ effects_NNS
          on_IN immune_JJ cells_NNS carrying_VBG the_DT IL-_NNP 2_CD receptor_NN ,_, which_WDT in_IN turn_NN
          release_NN soluble_JJ factors_NNS and_CC /_NN or_CC activate_VBP other_JJ cells_NNS by_IN
          cell-cell_JJ interactions_NNS ._. Thus_RB ,_, to_TO match_VB as_RB closely_RB as_IN
          possible_JJ the_DT 
          in_IN vitro_NN conditions_NNS with_IN those_DT
          occurring_VBG 
          in_IN vivo_NN ,_, we_PRP stimulated_VBN
          lymphocyte_NN /_NN monocyte-enriched_JJ PBMC_NNP preparations_NNS with_IN 6_CD ,_, 000_CD
          IU_NNP /_NN ml_NN IL-_NNP 2_CD in_IN serum-free_JJ medium_NN ._. This_DT concentration_NN
          approximates_VBZ the_DT pharmacokinetic_JJ distribution_NN of_IN IL-_NNP 2_CD
          following_VBG intravenous_JJ bolus_JJ administration_NN with_IN mean_NN peak_NN
          levels_NNS around_IN 250_CD ng_NN /_NN ml_NN ,_, corresponding_JJ to_TO approximately_RB
          5_CD ,_, 000_CD lU_NN /_NN ml_NN [_NN 19_CD ]_NN ._. This_DT time-course_JJ analysis_NN identified_VBD
          155_CD genes_NNS expressed_VBD more_RBR than_IN threefold_RB over_IN pre-_NN IL-_NNP 2_CD
          samples_NNS (_( Figure_NN 2_LS )_) ._. According_VBG to_TO their_PRP$ kinetics_NNS of_IN
          expression_NN ,_, the_DT large_JJ majority_NN of_IN genes_NNS were_VBD identifiable_JJ
          approximately_RB 3_CD hours_NNS after_IN IL-_NNP 2_CD exposure_NN ,_, with_IN the_DT
          exception_NN of_IN a_DT subgroup_NN including_VBG transcription_NN and_CC
          regulatory_JJ factors_NNS (_( c-_NN Fos_NNP ,_, MKP_NNP 1_LS )_) which_WDT underwent_VBD early_JJ
          and_CC short-lived_JJ upregulation_NN ._. An_DT overview_NN of_IN the_DT genes_NNS
          most_RBS consistently_RB affected_VBN by_IN IL-_NNP 2_CD therapy_NN revealed_VBD a_DT
          large_JJ array_NN of_IN transcripts_NNS with_IN functions_NNS ranging_VBG from_IN
          regulation_NN of_IN cell_NN division_NN and_CC apoptosis_NNS to_TO the_DT
          secretion_NN of_IN immune-stimulatory_JJ and_CC /_NN or_CC pro-inflammatory_JJ
          factors_NNS ._. In_IN addition_NN ,_, several_JJ surface_NN activation_NN markers_NNS
          in_IN lymphocytes_NNS and_CC monocytes_NNS that_WDT may_MD influence_VB migration_NN
          and_CC interaction_NN with_IN other_JJ cells_NNS were_VBD induced_VBN ._. Thus_RB ,_, the_DT
          effects_NNS of_IN IL-_NNP 2_CD on_IN PBMC_NNP span_NN ,_, as_IN expected_VBN ,_, a_DT broad_JJ range_NN
          related_VBN to_TO the_DT function_NN of_IN several_JJ different_JJ types_NNS of_IN
          mononuclear_NN cells_NNS ._.
        
        
          Time-course_NNP analysis_NN of_IN lL-_NN 2_CD -_: induced_VBN gene_NN
          expression_NN in_IN PBMC_NNP in_IN vivo_NN
          A_DT similar_JJ time-course_JJ analysis_NN was_VBD performed_VBN in_IN the_DT
          patient_NN who_WP donated_VBD the_DT PBMC_NNP for_IN the_DT 
          in_IN vitro_NN time_NN course_NN ,_, by_IN obtaining_VBG
          blood_NN at_IN intervals_NNS following_VBG intravenous_JJ administration_NN
          of_IN the_DT first_JJ dose_NN of_IN IL-_NNP 2_CD (_( 720_CD ,_, 000_CD IU_NNP /_NN ml_NN )_) ._. The_DT blood_NN was_VBD
          separated_VBN by_IN density_NN gradient_NN ,_, which_WDT left_VBD a_DT population_NN of_IN
          cells_NNS enriched_JJ in_IN lymphocytes_NNS and_CC monocytes_NNS ._. In_IN the_DT 
          in_IN vivo_NN time_NN course_NN ,_, 167_CD genes_NNS
          displayed_VBD differential_NN expression_NN (_( >_NN 3_CD -_: fold_VB change_NN in_IN
          at_IN least_JJS 70_CD %_NN of_IN the_DT samples_NNS )_) with_IN IL-_NNP 2_CD treatment_NN ._. We_PRP then_RB
          compared_VBD the_DT expression_NN profiles_NNS in_IN the_DT 
          in_IN vivo_NN time_NN course_NN for_IN the_DT 155_CD
          genes_NNS differentially_RB expressed_VBD as_IN a_DT result_NN of_IN IL-_NNP 2_CD
          exposure_NN during_IN the_DT 
          in_IN vitro_NN time-course_JJ analysis_NN ._.
          Differences_NNS between_IN the_DT two_CD data_NN sets_NNS could_MD be_VB due_JJ to_TO
          shifts_NNS in_IN cell-subset_JJ frequencies_NNS 
          in_IN vivo_NN and_CC /_NN or_CC true_JJ alterations_NNS in_IN
          the_DT gene-expression_JJ profile_NN of_IN individual_JJ cells_NNS ._. We_PRP
          hypothesized_VBN that_IN expression_NN profiles_NNS concordant_NN 
          in_IN vitro_NN (_( where_WRB no_DT change_NN in_IN
          cell-subset_JJ frequency_NN is_VBZ observed_VBN )_) and_CC 
          in_IN vivo_NN may_MD represent_VB with_IN most_JJS
          confidence_NN the_DT pattern_NN of_IN gene_NN expression_NN induced_VBN by_IN
          IL-_NNP 2_CD ._. A_DT set_NN of_IN 93_CD out_IN of_IN 155_CD genes_NNS concordantly_RB expressed_VBD
          in_IN the_DT 
          in_IN vitro_NN and_CC 
          in_IN vivo_NN experiments_NNS were_VBD identified_VBN
          (_( Figure_NN 3_CD a_DT ,_, 3_CD b_SYM ,_, 3_CD c_SYM ,_, 3_CD d_SYM ,_, 3_CD e_SYM )_) by_IN cluster_NN analysis_NN of_IN the_DT
          combined_VBN 
          in_IN vitro_NN and_CC 
          in_IN vivo_NN time-course_JJ samples_NNS ._. Genes_NNP
          for_IN chemokines_NNS and_CC cytokines_NNS related_VBN to_TO inflammatory_JJ
          processes_VBZ (_( IP-_NNP 10_CD ,_, MIP-_NNP 1_CD β_NN ,_, MCP_NNP 1_CD ,_, MCP-_NNP 3_CD ,_,
          GM-CSF_NNP /_NN IL-_NNP 15_CD /_NN IL-_NNP 3_CD Rβ_NNP ,_, IL-_NNP 1_CD receptor_NN )_) showed_VBD a_DT concordant_NN
          early_JJ upregulation_NN 
          in_IN vitro_NN and_CC 
          in_IN vivo_NN ._. Downregulation_NNP of_IN growth_NN
          factors_NNS /_NN cell_NN cycle_NN /_NN transcription_NN factor-related_JJ genes_NNS
          (_( for_IN ERF-_NNP 2_CD ,_, CDC_NNP 16_CD ,_, L-M_NNP yc_NN )_) occurred_VBD in_IN a_DT similar_JJ fashion_NN 
          in_IN vitro_NN and_CC 
          in_IN vivo_NN ._. As_IN the_DT majority_NN of_IN genes_NNS
          appeared_VBD to_TO be_VB concordantly_RB expressed_VBN 
          in_IN vitro_NN and_CC 
          in_IN vivo_NN ,_, we_PRP postulate_NN that_IN ,_, for_IN
          these_DT at_IN least_JJS ,_, the_DT effect_NN of_IN IL-_NNP 2_CD on_IN gene_NN expression_NN
          overrides_NNS its_PRP$ effect_NN on_IN population_NN shift_NN ._. Although_IN
          variability_NN in_IN the_DT kinetics_NNS of_IN expression_NN of_IN individual_JJ
          gene_NN was_VBD noted_VBN 
          in_IN vivo_NN ,_, as_IN for_IN the_DT 
          in_IN vitro_NN time_NN course_NN ,_, the_DT 3_CD -_: hour_NN
          time_NN point_NN appeared_VBD to_TO yield_VB the_DT most_RBS comprehensive_JJ view_NN
          of_IN alterations_NNS in_IN gene-expression_JJ profile_NN following_VBG IL-_NNP 2_CD
          administration_NN ._. Thus_RB ,_, this_DT data_NNS point_NN was_VBD used_VBN in_IN a_DT
          larger_JJR cohort_NN of_IN patients_NNS to_TO identify_VB genes_NNS consistently_RB
          modulated_JJ by_IN IL-_NNP 2_CD administration_NN ._.
        
        
          Genes_NNP whose_WP$ expression_NN is_VBZ consistently_RB altered_VBN in_IN
          peripheral_JJ blood_NN following_VBG IL-_NNP 2_CD administration_NN
          The_DT expression_NN pattern_NN of_IN the_DT 155_CD genes_NNS identified_VBN by_IN
          the_DT 
          in_IN vitro_NN time_NN course_NN was_VBD evaluated_VBN
          in_IN PBMC_NNP samples_NNS obtained_VBD 3_CD hours_NNS after_IN IL-_NNP 2_CD
          administration_NN in_IN a_DT larger_JJR cohort_NN of_IN patients_NNS (_( Figure_NN 4_LS )_) ._.
          A_DT first_JJ node_NN including_VBG 52_CD genes_NNS consistently_RB upregulated_JJ
          (_( at_IN least_JJS 3_CD -_: fold_VB change_NN in_IN ≥_NN 70_CD %_NN of_IN samples_NNS )_) was_VBD
          identified_VBN ._. Of_IN these_DT genes_NNS ,_, all_DT but_CC 6_CD were_VBD included_VBN among_IN
          the_DT 93_CD genes_NNS coordinately_RB expressed_VBD in_IN the_DT 
          in_IN vitro_NN and_CC 
          in_IN vivo_NN time_NN courses_NNS (_( Figure_NN 3_LS )_) ._. A_DT
          second_JJ node_NN included_VBD 28_CD genes_NNS consistently_RB downregulated_JJ ,_,
          most_JJS of_IN them_PRP represented_VBD among_IN those_DT coordinately_RB
          downregulated_JJ in_IN the_DT time-course_JJ studies_NNS ._. These_DT data_NNS
          suggest_VBP that_IN the_DT genes_NNS identified_VBN were_VBD highly_RB
          representative_NN of_IN the_DT effects_NNS of_IN IL-_NNP 2_CD administration_NN on_IN
          circulating_VBG cells_NNS ._.
          For_IN some_DT genes_NNS it_PRP was_VBD possible_JJ to_TO extrapolate_NN a_DT
          potential_JJ cell_NN subset_NN responsible_JJ for_IN their_PRP$ expression_NN by_IN
          testing_VBG different_JJ mononuclear_NN cell_NN subsets_NNS separated_VBN by_IN
          negative_JJ selection_NN after_IN 
          in_IN vitro_NN exposure_NN to_TO IL-_NNP 2_CD
          (_( monocytes_NNS ,_, CD_NNP 4_CD -_: +_NN T_NN cells_NNS ,_, CD_NNP 8_CD +_NN T_NN cells_NNS ,_, total_JJ
          lymphocytes_NNS and_CC neutrophils_NNS ,_, respectively_RB ,_, under_IN the_DT
          orange_NN bar_NN ,_, Figure_NN 4_LS )_) ._. Several_JJ were_VBD selectively_RB expressed_VBN
          by_IN either_DT monocytes_NNS or_CC CD_NNP 4_CD and_CC /_NN or_CC CD_NNP 8_CD T_NN cells_NNS ._.
          Interestingly_RB ,_, IL-_NNP 2_CD also_RB appeared_VBD to_TO stimulate_VB the_DT
          expression_NN of_IN some_DT of_IN these_DT genes_NNS in_IN neutrophils_NNS ,_, which_WDT ,_,
          however_RB ,_, could_MD not_RB be_VB accounted_VBN for_IN in_IN the_DT analysis_NN of_IN
          PBMC_NNP samples_NNS enriched_JJ in_IN monocytes_NNS and_CC lymphocytes_NNS and_CC
          almost_RB completely_RB depleted_VBN of_IN neutrophils_NNS ._.
        
        
          Genes_NNP specifically_RB expressed_VBD in_IN the_DT tumor_NN
          microenvironment_NN in_IN response_NN to_TO IL-_NNP 2_CD
          administration_NN
          The_DT genes_NNS whose_WP$ expression_NN was_VBD consistently_RB altered_VBN in_IN
          PBMC_NNP following_VBG IL-_NNP 2_CD administration_NN were_VBD analyzed_VBN in_IN a_DT set_NN
          of_IN FNAs_NNP obtained_VBD from_IN the_DT same_JJ patients_NNS plus_CC an_DT
          additional_JJ group_NN of_IN patients_NNS (_( Figure_NN 4_LS )_) ._. Because_IN there_EX
          are_VBP practical_JJ limits_NNS on_IN the_DT number_NN of_IN FNAs_NNP that_WDT can_MD be_VB
          carried_VBN out_IN in_IN the_DT same_JJ lesion_NN without_IN causing_VBG excessive_JJ
          disturbance_NN of_IN its_PRP$ structure_NN ,_, we_PRP sampled_VBN lesions_NNS 3_CD hours_NNS
          after_IN one_CD dose_NN (_( first_JJ four_CD samples_NNS in_IN the_DT array_NN )_) and_CC four_CD
          doses_NNS (_( remaining_VBG six_CD samples_NNS )_) of_IN IL-_NNP 2_CD ._. The_DT fourth_JJ dose_NN
          (_( 24_CD hours_NNS after_IN the_DT administration_NN of_IN the_DT first_JJ )_) was_VBD
          selected_VBN as_IN a_DT later_JJ point_NN likely_JJ to_TO be_VB reached_VBN by_IN all_DT
          patients_NNS before_IN treatment_NN was_VBD discontinued_VBN because_IN of_IN
          limiting_VBG toxicity_NN [_NN 20_CD ]_NN ._. The_DT post-_NN IL-_NNP 2_CD FNA_NNP material_NN was_VBD
          co-hybridized_JJ with_IN reference_NN RNA_NNP obtained_VBD pre-_NN IL-_NNP 2_CD from_IN
          each_DT lesion_NN as_RB previously_RB discussed_VBN ._. Only_RB a_DT small_JJ
          proportion_NN of_IN these_DT genes_NNS were_VBD consistently_RB upregulated_JJ
          in_IN FNA_NNP samples_NNS and_CC belonged_VBD to_TO a_DT closely_RB related_VBN
          subcluster_NN consisting_VBG of_IN genes_NNS for_IN inflammatory_JJ
          chemokines_NNS (_( MCP-_NNP 1_CD ,_, MCP-_NNP 3_CD ,_, IP-_NNP 10_CD ,_, LD-_NNP 78_CD )_) and_CC interferon-γ_JJ
          (_( IFN-γ_NNP )_) -_: related_VBN genes_NNS (_( guanylate-binding_JJ protein_NN
          IFN-inducible_NNP ,_, MxA_NNP ,_, IP-_NNP 10_CD )_) ._. Analysis_NNP of_IN mechanically_RB
          separated_JJ subsets_NNS related_VBD their_PRP$ expression_NN to_TO activation_NN
          of_IN either_DT monocytes_NNS or_CC T_NN cells_NNS ._.
          Whereas_IN the_DT previous_JJ analysis_NN was_VBD based_VBN on_IN a_DT pool_NN of_IN
          genes_NNS identified_VBN by_IN studying_VBG the_DT effects_NNS of_IN IL-_NNP 2_CD on_IN
          circulating_VBG T_NN cells_NNS ,_, an_DT independent_JJ analysis_NN was_VBD carried_VBN
          out_IN by_IN selecting_VBG ,_, from_IN the_DT complete_JJ data_NN set_VBN ,_, genes_NNS whose_WP$
          expression_NN was_VBD preferentially_RB altered_VBN in_IN FNA_NNP samples_NNS
          following_VBG IL-_NNP 2_CD administration_NN ._. Genes_NNP were_VBD ranked_VBN
          according_VBG to_TO their_PRP$ median_JJ ratio_NN of_IN expression_NN among_IN all_DT
          FNA_NNP samples_NNS (_( FNAs_NNP obtained_VBD after_IN one_CD or_CC four_CD doses_NNS were_VBD
          pooled_VBN together_RB to_TO identify_VB genes_NNS associated_VBN with_IN IL-_NNP 2_CD
          administration_NN independent_JJ of_IN dose_NN number_NN )_) ._. The_DT 75_CD genes_NNS
          with_IN the_DT highest_JJS median_JJ ratio_NN and_CC the_DT 75_CD with_IN the_DT lowest_JJS
          were_VBD selected_VBN (_( Figure_NN 5_LS )_) ._. The_DT expression_NN of_IN most_JJS of_IN these_DT
          genes_NNS seemed_VBD to_TO be_VB specifically_RB modulated_JJ by_IN IL-_NNP 2_CD and_CC not_RB
          by_IN the_DT trauma_NN of_IN needle_NN aspiration_NN ,_, as_IN only_RB a_DT few_JJ
          differentially_RB expressed_VBD genes_NNS (_( in_IN parentheses_NNS in_IN Figure_NN
          5_LS )_) were_VBD detected_VBN in_IN control_NN FNA_NNP samples_NNS obtained_VBN at_IN
          24_CD -_: hour_NN intervals_NNS in_IN the_DT absence_NN of_IN IL-_NNP 2_CD
          administration_NN ._.
          Eisen_NNP 's_POS hierarchical_JJ clustering_VBG analysis_NN [_NN 21_CD ]_NN was_VBD
          applied_VBN to_TO this_DT data_NNS set_VBN to_TO compute_VB relatedness_NNS among_IN
          transcriptional_NN profiles_NNS of_IN different_JJ FNA_NNP samples_NNS ._. This_DT
          was_VBD done_VBN to_TO evaluate_VB whether_IN FNAs_NNP obtained_VBD sequentially_RB
          after_IN one_CD or_CC four_CD doses_NNS of_IN IL-_NNP 2_CD from_IN identical_JJ or_CC
          different_JJ lesions_NNS would_MD cluster_NN according_VBG to_TO time_NN of_IN
          sampling_VBG or_CC tissue_NN of_IN origin_NN ._. According_VBG to_TO this_DT data_NNS set_VBN ,_,
          based_VBN on_IN the_DT most_RBS consistently_RB expressed_VBD genes_NNS ,_, samples_NNS
          from_IN the_DT same_JJ lesion_NN clustered_VBN together_RB independently_RB of_IN
          time_NN ,_, suggesting_VBG that_IN profiles_NNS of_IN IL-_NNP 2_CD -_: induced_VBN genes_NNS tend_VBP
          to_TO be_VB lesion_NN specific_JJ throughout_IN IL-_NNP 2_CD therapy_NN ._. The_DT
          relationship_NN among_IN the_DT samples_NNS independent_JJ of_IN time_NN of_IN
          treatment_NN was_VBD even_RB more_RBR robust_JJ when_WRB the_DT all-data_JJ set_VBN was_VBD
          queried_VBN (_( data_NNS not_RB shown_VBN )_) ._. Different_JJ functional_JJ subsets_NNS of_IN
          genes_NNS were_VBD identified_VBN that_WDT included_VBD those_DT for_IN several_JJ
          chemokines_NNS (_( GRO-_NNP 1_CD ,_, MIG_NNP ,_, MCP-_NNP 1_CD ,_, MCP-_NNP 3_CD ,_, MIP_NNP 1_CD -_: α_NN ,_, MIP-β_NNP ,_,
          PARC_NNP ,_, IL-_NNP 8_CD )_) ,_, cytokine_NN receptors_NNS (_( C-CR-_NNP 1_CD ,_, IL-R_NNP ,_, IL-_NNP 1_CD R_NN
          antagonist_NN ,_, IL-_NNP 2_CD Rβ_NNP ,_, transforming_VBG growth_NN factor-β_JJ receptor_NN
          (_( TGFβR_NNP )_) ,_, IFNγR_NNP α_NN chain_NN )_) ,_, adhesion_NN molecules_NNS associated_VBN
          with_IN mononuclear_NN cell_NN migration_NN (_( CD_NNP 62_CD L_NNP ,_, VCAM-_NNP 1_CD ,_, CD_NNP 64_CD ,_,
          CD_NNP 29_CD )_) ,_, cytotoxic_JJ proteins_NNS in_IN granules_NNS produced_VBN by_IN
          activated_VBN monocytes_NNS (_( grancalcin_NN and_CC calgranulin_NN )_) and_CC
          several_JJ genes_NNS associated_VBN with_IN IFN-γ_NNP activity_NN ,_, such_JJ as_IN HLA_NNP
          class_NN II_NNP molecules_NNS and_CC IFN-regulatory_NNP or_CC responsive_JJ genes_NNS
          such_JJ as_IN those_DT for_IN MxA_NNP ,_, MxB_NNP and_CC IRF-_NNP 1_CD ._. Interestingly_RB ,_, no_DT
          genes_NNS associated_VBN with_IN apoptosis_NNS or_CC cell_NN proliferation_NN
          were_VBD identified_VBN ._. In_IN addition_NN ,_, no_DT evidence_NN of_IN migration_NN of_IN
          various_JJ immune-cell_JJ subsets_NNS was_VBD observed_VBN by_IN analyzing_VBG
          changes_NNS in_IN frequency_NN of_IN genes_NNS constitutively_RB expressed_VBN by_IN
          such_JJ cells_NNS (_( that_WDT is_VBZ ,_, CD_NNP 8_CD ,_, CD_NNP 4_CD ,_, CD_NNP 14_CD ,_, and_CC so_RB on_RB ,_, see_VB
          Figure_NN 1_LS )_) ._. Thus_RB ,_, the_DT early_JJ effects_NNS of_IN IL-_NNP 2_CD administration_NN
          are_VBP more_RBR associated_JJ with_IN an_DT inflammatory_JJ modulation_NN of_IN
          the_DT tumor_NN microenvironment_NN rather_RB than_IN with_IN specific_JJ
          migration_NN ,_, activation_NN and_CC /_NN or_CC proliferation_NN of_IN immune_JJ
          cells_NNS at_IN the_DT tumor_NN site_NN ._.
          To_TO identify_VB genes_NNS whose_WP$ upregulation_NN in_IN the_DT tumor_NN
          microenvironment_NN was_VBD time_NN and_CC /_NN or_CC dose_NN dependent_JJ we_PRP then_RB
          queried_VBN the_DT FNA_NNP data_NN set_VBN by_IN selecting_VBG genes_NNS
          differentially_RB expressed_VBD between_IN samples_NNS obtained_VBD 3_CD hours_NNS
          after_IN one_CD or_CC four_CD doses_NNS of_IN IL-_NNP 2_CD (_( unpaired_JJ sample_NN 
          t_NN -_: test_NN ,_, 
          p_NN 
          2_CD value_NN <_NN 0_CD ._. 05_CD )_) ._. The_DT cut-off_JJ 
          p_NN 
          2_CD value_NN of_IN <_NN 0_CD ._. 05_CD was_VBD arbitrarily_RB
          selected_VBN and_CC was_VBD not_RB corrected_VBN by_IN the_DT number_NN of_IN
          hypotheses_NNS tested_VBN (_( genes_NNS )_) ._. Thus_RB ,_, the_DT genes_NNS identified_VBN
          should_MD be_VB considered_VBN more_JJR as_IN an_DT exploratory_JJ finding_NN than_IN
          a_DT definitive_JJ proof_NN of_IN differential_NN expression_NN according_VBG
          to_TO dose_NN number_NN ._. Ratios_NNP were_VBD shown_VBN according_VBG to_TO the_DT
          central_JJ method_NN for_IN display_NN using_VBG a_DT normalization_NN factor_NN
          that_WDT emphasizes_VBZ differences_NNS in_IN expression_NN between_IN the_DT
          experimental_JJ groups_NNS analyzed_VBN by_IN resetting_VBG the_DT equality_NN
          parameter_NN (_( ratio_NN =_SYM 1_LS )_) to_TO the_DT mean_NN of_IN all_PDT the_DT experiments_NNS
          [_NN 22_CD ]_NN ._. In_IN this_DT fashion_NN ,_, 54_CD genes_NNS were_VBD identified_VBN (_( Figure_NN
          6_CD )_) ._. Interestingly_RB ,_, among_IN them_PRP we_PRP noted_VBD a_DT further_JJ
          upregulation_NN of_IN MHC_NNP molecules_NNS and_CC other_JJ
          interferon-inducible_JJ factors_NNS ._.
          Among_IN the_DT lesions_NNS analyzed_VBD one_CD underwent_VBD partial_JJ
          regression_NN (_( Figure_NN 7_CD a_DT )_) ._. To_TO explore_VB possible_JJ markers_NNS
          associated_VBN with_IN immune_JJ responsiveness_NNS we_PRP queried_VBN the_DT data_NNS
          set_VBN for_IN genes_NNS expressed_VBD differentially_RB in_IN the_DT responder_NN
          lesion_NN after_IN one_CD (_( M_NNP ._. F_NN ._. 1_LS )_) and_CC four_CD (_( M_NNP ._. F_NN ._. 4_LS )_) doses_NNS of_IN
          IL-_NNP 2_CD ._. Two_CD 
          t_NN -_: tests_NNS (_( two-tail-unequal_JJ
          variance_NN )_) were_VBD carried_VBN out_IN comparing_VBG M_NNP ._. F_NN ._. 1_LS and_CC M_NNP ._. F_NN ._. 4_LS ,_,
          respectively_RB ,_, with_IN the_DT rest_NN of_IN the_DT FNA_NNP samples_NNS ._. Also_RB in_IN
          this_DT case_NN ,_, a_DT cut-off_JJ 
          p_NN 
          2_CD value_NN of_IN <_NN 0_CD ._. 05_CD was_VBD arbitrarily_RB
          selected_VBN ,_, and_CC was_VBD not_RB corrected_VBN by_IN the_DT number_NN of_IN genes_NNS
          studied_VBN ._. Thus_RB ,_, the_DT findings_NNS have_VBP only_RB exploratory_JJ value_NN ._.
          In_IN this_DT fashion_NN ,_, 68_CD and_CC 102_CD genes_NNS were_VBD identified_VBN
          respectively_RB (_( Figure_NN 7_CD b_SYM )_) ,_, of_IN which_WDT four_CD were_VBD overlapping_VBG
          (_( two_CD expressed_VBD sequence_NN tags_NNS (_( ESTs_NNP )_) ,_, a_DT nuclear_JJ protein_NN
          (_( CHD_NNP 3_LS )_) and_CC a_DT sphingosine_NN kinase_NN type_NN 2_CD isoform_NN )_) ._. When_WRB a_DT
          similar_JJ analysis_NN was_VBD carried_VBN out_IN by_IN comparing_VBG each_DT of_IN the_DT
          non-responding_JJ lesions_NNS to_TO the_DT rest_NN ,_, the_DT average_NN of_IN genes_NNS
          differentially_RB expressed_VBD was_VBD 2_CD ±_NN 1_CD after_IN one_CD dose_NN and_CC 56_CD
          ±_NN 27_CD after_IN four_CD doses_NNS ._. From_IN the_DT group_NN of_IN genes_NNS
          differentially_RB expressed_VBD in_IN the_DT responder_NN lesion_NN after_IN
          four_CD doses_NNS of_IN IL-_NNP 2_CD ,_, 19_CD were_VBD identified_VBN with_IN the_DT highest_JJS
          ratio_NN of_IN expression_NN ._. Among_IN these_DT 19_CD genes_NNS ,_, those_DT for_IN
          NKG_NNP 5_CD ,_, T-_NNP cell_NN receptor_NN α_NN chain_NN ,_, and_CC HLA_NNP class_NN II_NNP related_VBD
          transcripts_NNS appeared_VBD of_IN particular_JJ interest_NN because_IN they_PRP
          have_VBP been_VBN found_VBN to_TO be_VB upregulated_JJ in_IN the_DT context_NN of_IN acute_JJ
          rejection_NN of_IN renal_JJ allografts_NNS [_NN 23_CD ,_, 24_CD ]_NN ._. In_IN addition_NN ,_,
          three_CD were_VBD associated_VBN with_IN IL-_NNP 2_CD -_: dependent_JJ NK-cell_NNP
          activation_NN :_: NK_NNP 4_CD ,_, CD_NNP 62_CD P-_NNP selectin_NN ,_, and_CC galectin_NN 1_CD ,_, as_RB
          recently_RB observed_VBD when_WRB purified_JJ NK_NNP cells_NNS were_VBD exposed_VBN to_TO
          IL-_NNP 2_CD (_( S_NNP ._. Mocellin_NNP ,_, M_NNP ._. C_NNP ._. P_NN ._. and_CC F_NN ._. M_NNP ._. M_NNP ._. ,_, unpublished_JJ
          observations_NNS )_) ._.
        
      
      
        Discussion_NNP
        The_DT goal_NN of_IN this_DT study_NN was_VBD to_TO dissect_NN the_DT events_NNS
        following_VBG administration_NN of_IN high-dose_JJ IL-_NNP 2_CD for_IN therapeutic_JJ
        purposes_NNS ._. In_IN particular_JJ ,_, we_PRP were_VBD interested_JJ in_IN comparing_VBG
        the_DT systemic_JJ effects_NNS of_IN IL-_NNP 2_CD as_IN reflected_VBN by_IN the_DT
        transcriptional_NN profile_NN of_IN circulating_VBG mononuclear_NN cells_NNS
        with_IN the_DT effects_NNS observable_JJ within_IN the_DT tumor_NN
        microenvironment_NN ._. This_DT was_VBD achieved_VBN by_IN serial_NN sampling_VBG of_IN
        blood_NN and_CC tumor_NN samples_NNS to_TO follow_VB the_DT dynamic_JJ changes_NNS
        occurring_VBG during_IN the_DT course_NN of_IN IL-_NNP 2_CD administration_NN ._. The_DT
        results_NNS suggest_VBP that_IN IL-_NNP 2_CD exerts_NNS a_DT broad_JJ range_NN of_IN effects_NNS
        on_IN circulating_VBG cells_NNS ._. These_DT systemic_JJ effects_NNS have_VBP
        downstream_JJ repercussions_NNS ,_, only_RB a_DT few_JJ of_IN which_WDT were_VBD
        reflected_VBN in_IN changes_NNS in_IN gene_NN expression_NN at_IN the_DT tumor_NN site_NN ._.
        Analysis_NNP of_IN the_DT genes_NNS identified_VBN as_IN affected_VBN by_IN IL-_NNP 2_CD
        administration_NN suggested_VBD that_IN IL-_NNP 2_CD exerts_NNS its_PRP$ effect_NN at_IN the_DT
        target_NN site_NN by_IN causing_VBG activation_NN of_IN monocytes_NNS ._. This_DT could_MD
        be_VB best_JJS explained_VBN by_IN the_DT secondary_JJ release_NN of_IN
        pro-inflammatory_JJ substances_NNS such_JJ as_IN IFN-γ_NNP and_CC IL-_NNP 1_CD by_IN
        circulating_VBG or_CC intra-tumoral_JJ lymphoid_NN cells_NNS ,_, as_IN most_JJS of_IN the_DT
        genes_NNS identified_VBN are_VBP known_VBN to_TO be_VB responsive_JJ to_TO the_DT effect_NN
        of_IN either_DT of_IN these_DT cytokines_NNS ._.
        These_DT pro-inflammatory_JJ cytokines_NNS are_VBP probably_RB
        responsible_JJ for_IN the_DT direct_JJ activation_NN of_IN monocytes_NNS ,_, as_IN
        suggested_VBN by_IN the_DT upregulation_NN of_IN CD_NNP 64_CD and_CC IL-_NNP 1_CD R_NN (_( Figure_NN 8_CD )_) ._.
        In_IN addition_NN ,_, gene_NN profiling_VBG identified_VBN genes_NNS whose_WP$
        expression_NN is_VBZ most_RBS probably_RB dependent_JJ upon_IN IL-_NNP 1_CD and_CC IFN-γ_NNP
        rather_RB than_IN IL-_NNP 2_CD (_( genes_NNS for_IN MHC_NNP molecules_NNS ,_, HSP_NNP 70_CD ,_, MxA_NNP ,_, MxB_NNP
        and_CC other_JJ IFN-inducible_NNP proteins_NNS )_) ._. It_PRP is_VBZ possible_JJ that_DT
        macrophage_NN activation_NN is_VBZ followed_VBN by_IN release_NN of_IN
        pro-inflammatory_JJ chemokines_NNS such_JJ as_IN IL-_NNP 8_CD ,_, MCP-_NNP 3_CD ,_, MIP-_NNP 1_CD α_NN ,_,
        MIP-β_NNP and_CC MIG_NNP ._. These_DT indirect_JJ effects_NNS of_IN IL-_NNP 2_CD within_IN the_DT
        tumor_NN microenvironment_NN seem_VBP also_RB to_TO affect_VB the_DT activation_NN
        of_IN dendritic_JJ cells_NNS (_( DCs_NNP )_) through_IN the_DT expression_NN of_IN
        PARC_NNP /_NN MCP_NNP 4_CD ._. Finally_RB ,_, activation_NN of_IN macrophages_NNS results_NNS in_IN
        the_DT upregulation_NN of_IN the_DT expression_NN of_IN molecules_NNS with_IN lytic_JJ
        activity_NN ,_, such_JJ as_IN calgranulin_NN and_CC grancalcin_NN ._. Although_IN it_PRP
        is_VBZ possible_JJ that_IN the_DT downstream_JJ effects_NNS noted_VBD after_IN IL-_NNP 2_CD
        administration_NN could_MD be_VB attributed_VBN to_TO stimulation_NN of_IN tumor_NN
        cells_NNS ,_, exposure_NN of_IN three_CD melanoma_NN cell_NN lines_NNS (_( LF_NNP 1_CD TU_NNP ,_, 624_CD ._. 38_CD
        and_CC A_DT 375_CD )_) to_TO supernatant_NN from_IN IL-_NNP 2_CD -_: conditioned_VBN PBMC_NNP
        identified_VBD transcriptional_NN changes_NNS only_RB in_IN a_DT small_JJ
        proportion_NN of_IN these_DT genes_NNS (_( for_IN IFI-_NNP 16_CD ,_, IFNγR_NNP 2_CD and_CC
        TGF-β-inducible_NNP protein_NN ,_, data_NNS not_RB shown_VBN )_) ._. The_DT results_NNS ,_,
        therefore_RB ,_, suggest_VBP that_IN IL-_NNP 2_CD exerts_NNS its_PRP$ primary_JJ role_NN at_IN
        tumor_NN sites_NNS through_IN the_DT release_NN of_IN pro-inflammatory_JJ
        cytokines_NNS ._. On_IN the_DT basis_NN of_IN the_DT transcriptional_NN profile_NN
        identified_VBD ,_, we_PRP postulate_NN that_IN IL-_NNP 1_CD and_CC IFN-γ_NNP are_VBP the_DT most_RBS
        likely_JJ cytokines_NNS responsible_JJ for_IN this_DT phenomenon_NN ._. These_DT in_IN
        turn_NN activate_VBP a_DT local_JJ inflammation_NN ,_, probably_RB through_IN
        induction_NN of_IN monocytes_NNS and_CC macrophages_NNS ._. This_DT inflammatory_JJ
        process_NN can_MD subsequently_RB help_VB recruit_VB immune_JJ cells_NNS from_IN the_DT
        periphery_NN and_CC /_NN or_CC activate_VBP locally_RB infiltrating_VBG cells_NNS ._. This_DT
        hypothesis_NNS is_VBZ appealing_VBG because_IN it_PRP converges_NNS on_IN IFN-γ_NNP as_IN a_DT
        central_JJ mediator_NN of_IN immune_JJ regulation_NN within_IN the_DT tumor_NN
        microenvironment_NN ._. Recent_JJ murine_NN experiments_NNS have_VBP shown_VBN that_IN
        IFN-γ_NNP may_MD be_VB the_DT central_JJ mediator_NN of_IN immune_JJ surveillance_NN in_IN
        the_DT immunocompetent_NN host_NN [_NN 25_CD ]_NN ._. This_DT cytokine_NN could_MD
        possibly_RB also_RB have_VB a_DT central_JJ role_NN in_IN therapeutic_JJ settings_NNS ._.
        It_PRP may_MD have_VB broad_JJ downstream_JJ effects_NNS that_IN according_VBG to_TO our_PRP$
        findings_NNS can_MD be_VB best_JJS summarized_VBD as_IN activation_NN and_CC
        maturation_NN of_IN monocytes_NNS /_NN DCs_NNP in_IN concert_NN with_IN the_DT release_NN by_IN
        these_DT cells_NNS of_IN chemokines_NNS capable_JJ of_IN attracting_VBG lymphoid_NN
        cells_NNS to_TO the_DT tumor_NN ._. These_DT ,_, in_IN turn_NN ,_, may_MD complete_VB the_DT
        activation_NN of_IN cells_NNS of_IN the_DT monocytic_JJ lineage_NN ,_, which_WDT can_MD
        then_RB switch_VB their_PRP$ function_NN from_IN cross-tolerization_JJ to_TO
        cross-priming_JJ [_NN 26_CD ]_NN ._.
        A_DT particular_JJ subset_NN of_IN genes_NNS whose_WP$ expression_NN appeared_VBD
        to_TO be_VB associated_VBN with_IN a_DT clinical_JJ response_NN was_VBD noted_VBN ._.
        Although_IN this_DT observation_NN was_VBD based_VBN on_IN a_DT single_JJ lesion_NN ,_, we_PRP
        were_VBD surprised_VBN to_TO observe_VB among_IN them_PRP the_DT genes_NNS for_IN NKG_NNP 5_CD ,_,
        MHC_NNP class_NN II_NNP (_( which_WDT was_VBD upregulated_JJ beyond_IN the_DT level_NN noted_VBD
        in_IN non-responding_JJ samples_NNS )_) and_CC T-_NNP cell_NN receptor_NN ,_, which_WDT have_VBP
        all_DT been_VBN recently_RB associated_VBN with_IN acute_JJ rejection_NN of_IN renal_JJ
        allografts_NNS (_( [_NN 23_CD ,_, 24_CD ]_NN and_CC M_NNP ._. Sarwal_NNP ,_, unpublished_JJ data_NNS )_) ._. The_DT
        phenomenon_NN of_IN allograft_NN rejection_NN and_CC IL-_NNP 2_CD -_: induced_VBN tumor_NN
        rejection_NN may_MD not_RB only_RB be_VB characterized_VBN by_IN the_DT induction_NN of_IN
        a_DT vigorous_JJ inflammatory_JJ response_NN but_CC share_VB a_DT common_JJ
        cytotoxic_JJ effector_NN mechanism_NN (_( NK_NNP /_NN T-_NNP cell_NN degranulation_NN )_) that_WDT
        is_VBZ ultimately_RB responsible_JJ for_IN direct_JJ tissue_NN destruction_NN ._.
        This_DT observation_NN agrees_VBZ with_IN the_DT suggested_VBN synergistic_JJ role_NN
        of_IN IFN-γ_NNP and_CC effector_NN T_NN cells_NNS in_IN controlling_VBG tumor_NN growth_NN
        in_IN experimental_JJ models_NNS [_NN 25_CD ]_NN ._. 
        In_IN vitro_NN studies_NNS are_VBP presently_RB
        ongoing_JJ ,_, testing_NN whether_IN the_DT changes_NNS in_IN expression_NN profile_NN
        noted_VBD in_IN tumor_NN samples_NNS following_VBG IL-_NNP 2_CD administration_NN can_MD be_VB
        directly_RB ascribed_VBN to_TO the_DT effects_NNS of_IN IFN-γ_NNP and_CC /_NN or_CC IL-_NNP 1_CD on_IN
        monocytes_NNS ._.
      
      
        Conclusions_NNP
        The_DT results_NNS of_IN this_DT study_NN suggest_VBP that_IN IL-_NNP 2_CD
        administration_NN induces_VBZ inflammation_NN at_IN the_DT tumor_NN site_NN ,_, with_IN
        three_CD predominant_NN secondary_JJ effects_NNS :_: activation_NN of_IN
        antigen-presenting_JJ monocytes_NNS ;_: a_DT massive_JJ production_NN of_IN
        chemoattractants_NNS that_WDT may_MD recruit_VB other_JJ immune_JJ cells_NNS to_TO the_DT
        tumor_NN site_NN ,_, among_IN which_WDT are_VBP the_DT chemokines_NNS MIG_NNP and_CC PARC_NNP
        specific_JJ for_IN T_NN cells_NNS ;_: and_CC the_DT activation_NN of_IN lytic_JJ
        mechanisms_NNS ascribable_JJ to_TO monocytes_NNS (_( calgranulin_NN ,_,
        grancalcin_NN )_) and_CC NK_NNP cells_NNS (_( for_IN example_NN ,_, NKG_NNP 5_CD ,_, NK_NNP 4_LS )_) (_( Figure_NN
        8_CD )_) ._. In_IN practical_JJ terms_NNS ,_, these_DT results_NNS suggest_VBP that_IN systemic_JJ
        IL-_NNP 2_CD administration_NN may_MD facilitate_VB T-_NNP cell_NN effector_NN function_NN
        in_IN the_DT target_NN organ_NN not_RB by_IN sustaining_VBG their_PRP$ proliferation_NN ,_,
        as_RB presently_RB believed_VBN ,_, but_CC rather_RB by_IN promoting_VBG their_PRP$
        migration_NN and_CC by_IN providing_VBG a_DT milieu_NN conducive_JJ to_TO their_PRP$
        activation_NN 
        in_IN situ_NN through_IN activation_NN of_IN
        antigen-presenting_JJ cells_NNS ._. If_IN this_DT hypothesis_NNS is_VBZ correct_JJ ,_,
        then_RB adoptive_JJ transfer_NN of_IN effector_NN T_NN cells_NNS should_MD follow_VB ,_,
        rather_RB than_IN precede_VB as_IN at_IN present_JJ ,_, administration_NN of_IN
        systemic_JJ IL-_NNP 2_CD [_NN 27_CD ,_, 28_CD ]_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Selection_NN of_IN patients_NNS ,_, treatment_NN ,_, and_CC sampling_VBG of_IN
          PBMC_NNP and_CC FNAs_NNP
          PMBCs_NNP and_CC FNA_NNP biopsies_NNS of_IN melanoma_NN metastases_NNS were_VBD
          obtained_VBN from_IN patients_NNS with_IN metastatic_JJ melanoma_NN
          undergoing_VBG immunotherapy_NN with_IN high-dose_JJ IL-_NNP 2_CD at_IN the_DT
          Surgery_NNP Branch_NNP ,_, NCI_NNP (_( Bethesda_NNP ,_, MD_NNP )_) ._. IL-_NNP 2_CD (_( 720_CD ,_, 000_CD IU_NNP /_NN kg_NN )_)
          was_VBD administered_VBN by_IN 15_CD min_NN intravenous_JJ infusion_NN every_DT 8_CD h_NN
          for_IN up_IN to_TO 14_CD consecutive_JJ doses_NNS ,_, over_IN 5_CD days_NNS ,_, as_RB
          clinically_RB tolerated_JJ [_NN 29_CD ]_NN ._. The_DT effect_NN of_IN IL-_NNP 2_CD was_VBD
          analyzed_VBN in_IN four_CD patients_NNS '_POS PBMC_NNP ._. PBMC_NNP were_VBD obtained_VBN from_IN
          each_DT patient_NN by_IN apheresis_NNS before_IN IL-_NNP 2_CD infusion_NN and_CC at_IN 3_CD h_NN
          after_IN the_DT fourth_JJ dose_NN of_IN IL-_NNP 2_CD (_( patients_NNS H_NNP ._. P_NN ._. ,_, G_NNP ._. P_NN ._. ,_,
          C_NNP ._. P_NN ._. )_) ,_, with_IN the_DT exception_NN of_IN one_CD patient_NN who_WP was_VBD sampled_VBN
          twice_RB at_IN 3_CD h_NN after_IN the_DT first_JJ and_CC the_DT second_JJ dose_NN of_IN IL-_NNP 2_CD
          (_( C_NNP ._. P_NN ._. 1_LS ,_, C_NNP ._. P_NN ._. 3_LS )_) ._. Additionally_RB ,_, PBMC_NNP were_VBD obtained_VBN from_IN one_CD
          patient_NN (_( C_NNP ._. B_NNP ._. )_) 1_LS ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 6_CD and_CC 8_CD h_NN after_IN the_DT first_JJ dose_NN
          of_IN IL-_NNP 2_CD (_( 
          in_IN vivo_NN time_NN course_NN )_) ._. Serial_JJ FNA_NNP of_IN
          selected_VBN melanoma_NN metastases_NNS were_VBD obtained_VBN from_IN six_CD
          patients_NNS (_( three_CD of_IN whom_WP also_RB had_VBD paired_VBN PBMC_NNP samples_NNS )_)
          before_IN IL-_NNP 2_CD infusion_NN (_( C_NNP ._. F_NN ._. o_NN ,_, G_NNP ._. F_NN ._. o_NN ,_, H_NNP ._. F_NN ._. o_NN ,_, K_NNP ._. F_NN ._. o_NN ,_, L_NNP ._. F_NN ._. o_NN ,_,
          M_NNP ._. F_NN ._. o_NN )_) and_CC at_IN 3_CD h_NN after_IN the_DT first_JJ (_( C_NNP ._. F_NN ._. 1_LS ,_, K_NNP ._. F_NN ._. 1_LS ,_, l_NN ._. f_SYM ._. 1_LS ,_,
          M_NNP ._. F_NN ._. 1_LS )_) and_CC /_NN or_CC fourth_JJ dose_NN of_IN IL-_NNP 2_CD (_( G_NNP ._. F_NN ._. a_DT 4_CD ,_, G_NNP ._. F_NN ._. b_SYM 4_CD ,_, H_NNP ._. F_NN ._. 4_LS ,_,
          K_NNP ._. F_NN ._. 4_LS ,_, L_NNP ._. F_NN ._. 4_LS ,_, M_NNP ._. F_NN ._. 4_LS )_) ._. PBMC_NNP and_CC FNA_NNP samples_NNS obtained_VBN
          before_IN IL-_NNP 2_CD administration_NN were_VBD considered_VBN references_NNS ,_,
          and_CC those_DT obtained_VBN after_IN IL-_NNP 2_CD administration_NN were_VBD used_VBN as_IN
          targets_NNS for_IN microarray_NN analysis_NN
        
        
          Selection_NN of_IN the_DT time_NN window_NN and_CC cytokine_NN
          concentration_NN for_IN in_IN vitrostudies_NNS
          Selection_NN of_IN the_DT time_NN window_NN and_CC cytokine_NN
          concentration_NN for_IN 
          in_IN vitro_NN IL-_NNP 2_CD studies_NNS was_VBD based_VBN on_IN
          the_DT pharmacokinetics_NNS of_IN IL-_NNP 2_CD [_NN 19_CD ]_NN ,_, measuring_VBG
          biologically_RB active_JJ serum_NN IL-_NNP 2_CD levels_NNS after_IN
          administration_NN of_IN different_JJ doses_NNS of_IN IL-_NNP 2_CD ._. Patients_NNS
          receiving_VBG 720_CD ,_, 000_CD IU_NNP /_NN kg_NN IV_NNP bolus_JJ recombinant_JJ IL-_NNP 2_CD showed_VBD
          a_DT mean_JJ peak_NN IL-_NNP 2_CD level_NN of_IN 260_CD ±_NN 66_CD ng_NN /_NN ml_NN =_SYM 4_CD ,_, 680_CD ±_NN 1_CD ,_, 188_CD
          IU_NNP /_NN ml_NN (_( 18_CD IU_NNP =_SYM 1_CD ng_NN )_) ,_, which_WDT then_RB decayed_JJ with_IN time_NN ._.
          To_TO match_VB as_RB closely_RB as_IN possible_JJ the_DT 
          in_IN vitro_NN conditions_NNS with_IN those_DT
          occurring_VBG 
          in_IN
          vivo_NN ,_, lymphocyte_NN /_NN monocyte-enriched_JJ PBMC_NNP preparations_NNS
          were_VBD stimulated_VBN with_IN 6_CD ,_, 000_CD IU_NNP /_NN ml_NN IL-_NNP 2_CD in_IN serum-free_JJ
          medium_NN ._.
        
        
          In_IN vitrostudies_NNS
          PBMC_NNP obtained_VBD from_IN one_CD patient_NN (_( C_NNP ._. B_NNP ._. )_) by_IN apheresis_NNS
          before_IN administration_NN of_IN IL-_NNP 2_CD were_VBD seeded_VBN at_IN 6_CD ×_NN 10_CD 6_CD per_IN
          well_RB of_IN a_DT 24_CD -_: well_RB plate_NN in_IN OPTI-MEM_NNP medium_NN without_IN serum_NN
          supplementation_NN and_CC were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP in_IN the_DT
          presence_NN or_CC absence_NN of_IN 6_CD ,_, 000_CD IU_NNP /_NN ml_NN IL-_NNP 2_CD for_IN 0_CD or_CC 5_CD min_NN ,_,
          or_CC 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 6_CD and_CC 8_CD h_NN ._. At_IN each_DT time_NN point_NN adherent_NN
          monocytes_NNS were_VBD harvested_VBN with_IN trypsin_NN and_CC combined_VBN with_IN
          non-adherent_JJ cells_NNS ._. Adherent_NNP and_CC non-adherent_JJ cells_NNS were_VBD
          washed_VBN three_CD times_NNS with_IN PBS_NNP ,_, differential_NN counts_NNS were_VBD
          carried_VBN out_IN by_IN automated_VBN counting_VBG (_( Cell_NNP Dyn_NNP 4000_CD ,_, Abbott_NNP
          Diagnostics_NNPS ,_, Santa_NNP Clara_NNP ,_, CA_NNP )_) and_CC cells_NNS were_VBD resuspended_JJ
          in_IN lysis_NNS buffer_NN for_IN RNA_NNP isolation_NN (_( RNeasy_NNP ,_, Qiagen_NNP ,_,
          Valencia_NNP ,_, CA_NNP )_) ._. RNA_NNP was_VBD amplified_VBN using_VBG the_DT protocol_NN for_IN
          mRNA_NN amplification_NN and_CC probe_NN preparation_NN previously_RB
          published_VBD [_NN 17_CD ]_NN ._. Each_DT probe_NN /_NN test_NN sample_NN (_( antisense_NN RNA_NNP
          (_( aRNA_NN )_) obtained_VBN at_IN each_DT time_NN point_NN )_) was_VBD labeled_VBN with_IN Cy_NNP 5_CD
          and_CC mixed_VBN with_IN Cy_NNP 3_CD -_: labeled_VBN reference_NN sample_NN
          (_( non-stimulated_JJ PBMC_NNP obtained_VBD from_IN apheresis_NNS before_IN IL-_NNP 2_CD
          administration_NN )_) ._.
        
        
          In_IN vivostudies_NNS
          Peripheral_NNP blood_NN cells_NNS were_VBD sampled_VBN from_IN patient_NN C_NNP ._. B_NNP ._.
          during_IN course_NN 1_CD ,_, cycle_NN 1_CD ,_, of_IN high-dose_JJ IV_NNP bolus_JJ IL-_NNP 2_CD
          therapy_NN ._. A_DT 10_CD -_: ml_NN blood_NN sample_NN was_VBD drawn_VBN at_IN 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 6_CD
          and_CC 8_CD h_NN directly_RB into_IN a_DT BD_NNP vacutainer_NN ™_NN CPT_NNP ™_NN /_NN sodium_NN
          heparin_NN tube_NN (_( BD_NNP ,_, Franklin_NNP Lakes_NNP ,_, NJ_NNP )_) ._. Fresh_NNP blood_NN was_VBD
          similarly_RB drawn_VBN and_CC processed_VBN from_IN patients_NNS H_NNP ._. P_NN ._. ,_, G_NNP ._. P_NN ._.
          and_CC C_NNP ._. P_NN ._. at_IN the_DT 3_CD -_: h_NN time_NN point_NN during_IN IL-_NNP 2_CD
          administration_NN ._. In_IN all_DT cases_NNS ,_, automated_VBN differential_NN
          counts_NNS were_VBD made_VBN before_IN density-gradient_JJ separation_NN of_IN
          mononuclear_NN cells_NNS in_IN CPT_NNP tubes_NNS according_VBG to_TO the_DT
          manufacturer_NN 's_POS protocol_NN ._. The_DT recovered_VBN mononuclear_NN cells_NNS
          were_VBD washed_VBN three_CD times_NNS with_IN PBS_NNP and_CC resuspended_JJ in_IN lysis_NNS
          buffer_NN for_IN RNA_NNP isolation_NN (_( RNeasy_NNP ,_, Qiagen_NNP )_) ._. RNA_NNP was_VBD
          amplified_VBN using_VBG the_DT protocol_NN for_IN mRNA_NN amplification_NN and_CC
          probe_NN preparation_NN according_VBG to_TO a_DT previously_RB described_VBN
          procedure_NN [_NN 17_CD ]_NN ,_, with_IN some_DT additional_JJ modifications_NNS
          described_VBD below_IN ._. Each_DT probe_NN /_NN test_NN PBMC_NNP sample_NN was_VBD labeled_VBN
          with_IN Cy_NNP 5_CD and_CC mixed_VBN with_IN Cy_NNP 3_CD -_: labeled_VBN reference_NN sample_NN
          obtained_VBN from_IN apheresis_NNS before_IN IL-_NNP 2_CD administration_NN ._. FNA_NNP
          material_NN was_VBD processed_VBN similarly_RB and_CC hybridized_JJ to_TO
          microarrays_NNS using_VBG as_IN reference_NN sample_NN FNA_NNP material_NN
          obtained_VBN before_IN IL-_NNP 2_CD administration_NN ._. In_IN brief_JJ ,_, FNA_NNP of_IN
          selected_VBN metastases_NNS were_VBD carried_VBN out_IN before_IN and_CC 3_CD h_NN after_IN
          IL-_NNP 2_CD administration_NN as_RB previously_RB described_VBD [_NN 30_CD ]_NN ._. The_DT
          FNA_NNP material_NN was_VBD immediately_RB resuspended_JJ in_IN ice-cold_JJ
          Iscove_NNP 's_POS medium_NN without_IN serum_NN supplementation_NN ,_, and_CC
          subsequently_RB washed_VBN in_IN PBS_NNP before_IN RNA_NNP isolation_NN ._.
        
        
          Stimulation_NNP of_IN PBMC_NNP with_IN IL-_NNP 2_CD and_CC separation_NN of_IN
          single_JJ leukocyte_NN subsets_NNS
          Monocytes_NNP ,_, CD_NNP 8_CD and_CC CD_NNP 4_CD T-_NNP cell_NN subsets_NNS were_VBD separated_JJ
          from_IN patient_NN C_NNP ._. B_NNP ._. 's_POS PBMC_NNP (_( pre-_NN IL-_NNP 2_CD treatment_NN )_) after_IN
          exposure_NN of_IN PBMC_NNP to_TO IL-_NNP 2_CD ._. In_IN brief_JJ ,_, 2_CD ×_NN 10_CD 8_CD PBMC_NNP were_VBD
          thawed_JJ ,_, washed_VBD twice_RB in_IN a_DT 50_CD :_: 50_CD mixture_NN of_IN OPTI-MEM_NNP and_CC
          Plasbumin_NNP (_( Bayer_NNP ,_, West_NNP Heven_NNP ,_, CT_NNP )_) and_CC incubated_JJ for_IN 3_CD h_NN
          in_IN a_DT T_NN 175_CD flask_NN in_IN 50_CD ml_NN serum-free_JJ OPTI-MEM_NNP in_IN the_DT
          presence_NN or_CC absence_NN of_IN 6_CD ,_, 000_CD IU_NNP IL-_NNP 2_CD per_IN ml_NN OPTI-MEM_NNP ._.
          After_IN incubation_NN ,_, non-adherent_JJ cells_NNS were_VBD collected_VBN ,_,
          washed_VBN in_IN PBS_NNP ,_, and_CC CD_NNP 4_CD and_CC CD_NNP 8_CD T-_NNP cell_NN subsets_NNS were_VBD
          separated_VBN by_IN high-affinity_JJ negative_JJ selection_NN using_VBG CD_NNP 4_CD
          and_CC CD_NNP 8_CD subset_NN columns_NNS (_( R_NN &_CC D_NNP System_NNP ,_, Minneapolis_NNP ,_, MN_NNP )_)
          according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._. Purified_NNP
          IL-_NNP 2_CD -_: stimulated_VBN and_CC unstimulated_JJ CD_NNP 4_CD and_CC CD_NNP 8_CD T_NN cells_NNS were_VBD
          washed_VBN twice_RB in_IN PBS_NNP and_CC resuspended_JJ in_IN 350_CD ml_NN RNeasy_NNP
          lysis_NNS buffer_NN (_( Qiagen_NNP )_) for_IN RNA_NNP isolation_NN and_CC probe_NN
          preparation_NN as_RB previously_RB described_VBD ._. The_DT purity_NN of_IN the_DT
          recovered_VBN T-_NNP cell_NN subsets_NNS was_VBD assessed_VBN by_IN FACS_NNP analysis_NN
          and_CC ranged_VBD between_IN 79_CD and_CC 83_CD %_NN for_IN CD_NNP 4_CD T_NN cells_NNS and_CC 89_CD and_CC
          90_CD %_NN for_IN CD_NNP 8_CD T_NN cells_NNS ._. The_DT remaining_VBG adherent_NN monocytes_NNS
          were_VBD washed_VBN twice_RB in_IN PBS_NNP and_CC simultaneously_RB harvested_VBN and_CC
          lysed_JJ for_IN RNA_NNP isolation_NN using_VBG 2_CD ._. 1_CD ml_NN RNeasy_NNP lysis_NNS buffer_NN
          per_IN T_NN 175_CD flask_NN ,_, according_VBG to_TO the_DT manufacturer_NN 's_POS
          protocol_NN ._.
        
        
          Direct_JJ separation_NN of_IN neutrophils_NNS from_IN normal_JJ donor_NN
          buffy_NN coats_NNS
          A_DT 20_CD -_: ml_NN buffy_NN coat_NN suspension_NN was_VBD overlayed_JJ onto_IN 20_CD ml_NN
          HESPAN_NNP (_( B_NNP ._. Broun_NNP Medical_NNP Inc_NNP ,_, Melsunger_NNP ,_, Germany_NNP )_) ,_, mixed_JJ
          rapidly_RB ,_, and_CC incubated_JJ for_IN 30_CD min_NN at_IN room_NN temperature_NN to_TO
          separate_VB red_JJ blood_NN cells_NNS ._. After_IN incubation_NN ,_, the_DT
          supernatant_NN was_VBD carefully_RB removed_VBN and_CC washed_VBN in_IN Hanks_NNP 's_POS
          balanced_JJ salt_NN solution_NN ._. The_DT cell_NN suspension_NN was_VBD then_RB
          over-layed_JJ onto_IN 15_CD ml_NN of_IN lymphocyte-separation_JJ medium_NN
          (_( LSM_NNP ;_: Organon_NNP Teknica_NNP Corp_NNP ._. ,_, Durham_NNP ,_, NC_NNP )_) for_IN separation_NN
          of_IN a_DT monocyte_NN /_NN lymphocyte_NN interphase_NN and_CC a_DT granulocyte_NN /_NN red_JJ
          blood_NN cell_NN pellet_NN ._. Granulocytes_NNP were_VBD separated_JJ from_IN red_JJ
          blood_NN cells_NNS by_IN ACK_NNP lysis_NNS (_( Biofluids_NNP International_NNP ,_,
          Rockville_NNP ,_, MD_NNP )_) at_IN 4_CD °_NN C_NNP for_IN 10_CD -_: 15_CD min_NN ._. Purified_NNP
          granulocytes_NNS were_VBD then_RB resuspended_JJ in_IN 700_CD μl_NN RNeasy_NNP lysis_NNS
          buffer_NN for_IN probe_NN preparation_NN as_IN described_VBN above_IN ._. The_DT
          purity_NN of_IN the_DT granulocyte_NN preparation_NN and_CC the_DT neutrophil_NN
          content_NN was_VBD assessed_VBN by_IN immunocytochemistry_NN using_VBG DIFF_NNP
          quick_JJ staining_VBG according_VBG to_TO the_DT manufacturer_NN 's_POS protocol_NN
          (_( American_NNP Scientific_NNP Products_NNPS ,_, McGraw_NNP Park_NNP ,_, IL_NNP )_) ._.
        
        
          Permeability_NNP assay_NN
          Permeability_NNP was_VBD assayed_JJ using_VBG 6_CD -_: well_RB Falcon_NNP
          permeability_NN chamber_NN inserts_NNS positioned_VBN in_IN 6_CD -_: well_RB plates_NNS
          (_( Falcon-_NNP BD_NNP Biosciences_NNP ,_, Bedford_NNP ,_, MA_NNP )_) according_VBG to_TO the_DT
          manufacturer_NN 's_POS instructions_NNS ._. HUVEC_NNP were_VBD plated_JJ in_IN the_DT
          luminal_NN chamber_NN at_IN 8_CD ×_NN 10_CD 5_CD /_NN well_RB /_NN 2_CD ml_NN EGM-_NNP 2_CD medium_NN
          (_( Clonetics_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP )_) on_IN day_NN 0_CD and_CC incubated_JJ at_IN 37_CD °_NN C_NNP
          in_IN 5_CD %_NN CO_NNP 
          2_CD for_IN 48_CD h_NN ._. On_IN day_NN 2_CD ,_, 4_CD ×_NN 10_CD
          6_CD PBMC_NNP /_NN well_RB were_VBD added_VBN on_IN top_NN of_IN the_DT HUVEC_NNP monolayer_NN in_IN
          the_DT presence_NN or_CC absence_NN of_IN IL-_NNP 2_CD (_( 6_CD ,_, 000_CD IU_NNP /_NN ml_NN )_) and_CC
          incubated_JJ for_IN 3_CD h_NN ._. Control_NN wells_NNS consisted_VBD of_IN media_NNS
          supplemented_JJ with_IN or_CC without_IN IL-_NNP 2_CD in_IN the_DT absence_NN of_IN PBMC_NNP ._.
          After_IN incubation_NN ,_, the_DT content_NN of_IN the_DT luminal_NN chamber_NN was_VBD
          cleared_VBN and_CC the_DT HUVEC_NNP monolayer_NN was_VBD washed_VBN once_RB with_IN 1_CD ×_NN
          Dulbecco_NNP PBS_NNP (_( DPBS_NNP )_) (_( Biofluids_NNP )_) ._. Two_CD milliliters_NNS of_IN EBM-_NNP 2_CD
          medium_NN +_NN 1_CD %_NN human_JJ plasma_NN were_VBD then_RB added_VBN to_TO the_DT monolayer_NN
          and_CC the_DT cells_NNS were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP in_IN 5_CD %_NN CO_NNP 
          2_CD for_IN 1_CD h_NN ._. After_IN incubation_NN ,_, the_DT EBM_NNP
          medium_NN was_VBD then_RB aspirated_JJ from_IN the_DT luminal_NN chamber_NN and_CC
          1_CD ._. 5_CD ml_NN Evans_NNP Blue_NNP dye_NN in_IN DPBS_NNP /_NN 0_CD ._. 1_LS BSA_NNP was_VBD added_VBN ._. DPBS_NNP (_( 2_CD
          ml_NN )_) was_VBD added_VBN into_IN the_DT abluminal_NN (_( bottom_NN )_) chamber_NN
          followed_VBN by_IN 1_CD h_NN incubation_NN ._. The_DT insert_NN containing_VBG the_DT
          HUVEC_NNP monolayer_NN was_VBD then_RB discarded_VBN ,_, and_CC the_DT optical_JJ
          density_NN (_( OD_NNP )_) of_IN the_DT fluid_NN in_IN the_DT abluminal_NN chamber_NN was_VBD
          measured_VBN at_IN 620_CD nm_NN using_VBG DPBS_NNP alone_RB as_IN blank_JJ control_NN ._.
          Permeability_NNP was_VBD measured_VBN as_IN increase_NN in_IN OD_NNP of_IN abluminal_NN
          chamber_NN medium_NN due_JJ to_TO migration_NN of_IN Evans_NNP Blue_NNP dye_NN from_IN
          the_DT luminal_NN chamber_NN ._. Each_DT experimental_JJ condition_NN was_VBD run_VBN
          in_IN triplicate_NN and_CC repeated_VBN in_IN three_CD independent_JJ
          experiments_NNS ._. Changes_NNS in_IN permeability_NN with_IN 
          p_NN <_NN 0_CD ._. 01_CD were_VBD considered_VBN
          significant_JJ (_( Student_NNP 
          t_NN -_: test_NN )_) ._.
        
        
          Differential_NNP stimulation_NN of_IN PBMC_NNP with_IN IL-_NNP 2_CD for_IN
          supernatant_NN collection_NN
          PBMC_NNP collected_VBD from_IN apheresis_NNS before_IN IL-_NNP 2_CD treatment_NN
          were_VBD obtained_VBN from_IN one_CD patient_NN (_( L_NNP ._. B_NNP ._. )_) ,_, washed_VBD twice_RB in_IN a_DT
          50_CD :_: 50_CD mixture_NN of_IN OPTI-MEM_NNP and_CC Plasbumin_NNP and_CC incubated_JJ for_IN
          3_CD and_CC 24_CD h_NN at_IN 1_CD ×_NN 10_CD 8_CD cells_NNS /_NN T_NN 175_CD flask_NN in_IN 50_CD ml_NN
          serum-free_JJ OPTI-MEM_NNP in_IN the_DT presence_NN or_CC absence_NN of_IN 6_CD ,_, 000_CD
          IU_NNP IL-_NNP 2_CD per_IN ml_NN OPTI-MEM_NNP ._. After_IN each_DT incubation_NN ,_,
          supernatants_NNS containing_VBG non-adherent_JJ cells_NNS were_VBD collected_VBN
          and_CC centrifuged_JJ twice_RB to_TO separate_VB the_DT non-adherent_JJ
          leukocyte_NN populations_NNS and_CC frozen_VBN at_IN -_: 30_CD °_NN C_NNP for_IN stimulation_NN
          of_IN HUVEC_NNP monolayers_NNS ._.
        
        
          Exposure_NNP of_IN HUVEC_NNP to_TO supernatant_NN obtained_VBN from_IN PBMC_NNP
          stimulated_VBN with_IN IL-_NNP 2_CD
          Supernatants_NNP obtained_VBD from_IN PBMC_NNP exposed_VBD to_TO IL-_NNP 2_CD or_CC
          OPTI-MEM_NNP (_( control_NN )_) for_IN 3_CD and_CC 24_CD h_NN were_VBD overlayed_JJ on_IN
          confluent_NN monolayers_NNS of_IN HUVEC_NNP in_IN T_NN 175_CD flasks_NNS (_( Falcon_NNP )_) at_IN
          37_CD °_NN C_NNP in_IN 5_CD %_NN CO_NNP 
          2_CD for_IN 3_CD h_NN ._. After_IN incubation_NN ,_, 1_CD ._. 4_CD -_: 2_CD ._. 1_LS
          ml_NN of_IN RNeasy_NNP lysis_NNS buffer_NN was_VBD added_VBN to_TO each_DT flask_NN to_TO lyse_NN
          the_DT adherent_NN cell_NN monolayers_NNS and_CC isolate_VB RNA_NNP for_IN
          microarray_NN probe_NN preparation_NN as_IN described_VBN below_IN ._.
        
        
          Probe_NNP preparation_NN and_CC hybridization_NN to_TO
          microarrays_NNS
          Total_NNP RNA_NNP was_VBD isolated_VBN using_VBG RNeasy_NNP minikits_NNS (_( Qiagen_NNP )_) ._.
          aRNA_NN was_VBD prepared_VBN from_IN total_JJ RNA_NNP (_( 0_CD ._. 5_LS -_: 3_CD μg_NN )_) according_VBG the_DT
          protocol_NN previously_RB described_VBN by_IN us_PRP [_NN 17_CD ]_NN ._. In_IN brief_JJ ,_, two_CD
          rounds_NNS of_IN amplification_NN were_VBD carried_VBN out_IN ,_, which_WDT consisted_VBD
          of_IN a_DT combination_NN of_IN 
          in_IN vitro_NN transcription_NN and_CC
          template-switching_JJ PCR_NNP ._. The_DT first_JJ round_NN combined_VBN reverse_VB
          transcription_NN using_VBG oligo-d_JJ T_NN (_( 15_CD )_) -_: T_NN 7_CD
          (_( 5_CD '_POS -_: AAACGACGGCCAGTGAATTGTAATACGACTCACTATAGGCGC-_NNP 3_CD '_POS )_) primer_NN
          and_CC template-switch_JJ primer_NN
          (_( 5_CD '_POS -_: AAGCAGTGGTATCAACGCAGAGTACGCGGG-_NNP 3_CD '_POS )_) (_( Clontech_NNP ,_, Palo_NNP
          Alto_NNP ,_, CA_NNP )_) catalyzed_JJ by_IN the_DT Superscript-_NNP 11_CD reverse_VB
          transcriptase_NN (_( Gibco-_NNP BRL_NNP )_) and_CC Advantage_NNP cDNA_NN polymerase_NN
          (_( Clontech_NNP )_) for_IN single-_NN and_CC double-strand_JJ cDNA_NN synthesis_NN
          respectively_RB ,_, with_IN 
          in_IN vitro_NN transcription_NN (_( Megascript_NNP
          kit_NN ,_, Ambion_NNP ,_, Austin_NNP ,_, TX_NNP )_) ._. The_DT second_JJ round_NN of_IN
          amplification_NN utilized_JJ 0_CD ._. 5_CD to_TO 1_CD μg_NN aRNA_NN as_IN starting_VBG
          material_NN and_CC resembled_JJ the_DT first_JJ round_NN ,_, except_IN for_IN random_JJ
          hexamer_NN pd_NN (_( N_NNP )_) 6_CD (_( Boehringer_NNP Mannheim_NNP ,_, Igelheim_NNP ,_, Germany_NNP )_)
          used_VBN in_IN the_DT reverse-transcription_JJ reaction_NN in_IN place_NN of_IN
          the_DT template-switch_JJ primer_NN ._. aRNA_NN (_( 3_CD ._. 5_LS -_: 5_CD μg_NN )_) obtained_VBN
          after_IN two_CD rounds_NNS of_IN amplification_NN was_VBD labeled_VBN in_IN a_DT
          reverse-transcription_JJ reaction_NN in_IN the_DT presence_NN of_IN
          Cy_NNP 3_CD -_: labeled_VBN (_( reference_NN sample_NN )_) or_CC Cy_NNP 5_CD (_( test_NN
          sample_NN )_) -_: labeled_VBN dUTP_NN (_( Amersham_NNP ,_, Piscataway_NNP ,_, NJ_NNP )_) ._.
          Test-reference_NNP sample_NN pairs_NNS were_VBD mixed_JJ and_CC co-hybridized_JJ
          to_TO 6_CD ,_, 500_CD -_: spot_NN microarrays_NNS ._.
        
        
          Microarray_NNP analysis_NN tools_NNS
          Hybridized_NNP arrays_NNS were_VBD scanned_JJ at_IN 10_CD -_: μm_NN resolution_NN on_IN
          a_DT GenePix_NNP 4000_CD scanner_NN (_( Axon_NNP Instruments_NNP )_) at_IN variable_JJ PMT_NNP
          voltage_NN to_TO obtain_VB maximal_NN signal_NN intensities_NNS with_IN <_NN 1_CD %_NN
          probe_NN saturation_NN ._. Resulting_NNP tiff_NN images_NNS were_VBD analyzed_VBN via_IN
          ArraySuite_NNP software_NN (_( National_NNP Human_NNP Genome_NNP Research_NNP
          Institute_NNP ,_, Bethesda_NNP ,_, MD_NNP )_) ._. Data_NNP was_VBD analyzed_VBN using_VBG Cluster_NNP
          and_CC Tree_NN View_NNP software_NN by_IN Michael_NNP Eisen_NNP [_NN 21_CD ]_NN ._.
        
      
      
        Additional_JJ data_NNS files_NNS
        An_DT additional_JJ filecontaining_VBG the_DT identity_NN of_IN the_DT genes_NNS
        differentially_RB expressed_VBD in_IN the_DT M_NNP ._. F_NN ._. responding_VBG lesion_NN
        after_IN 1_CD (_( 68_CD genes_NNS )_) and_CC four_CD doses_NNS (_( 102_CD genes_NNS )_) of_IN IL-_NNP 2_CD is_VBZ
        available_JJ ._.
        Additional_JJ data_NNS file_VBP 1_CD
        Genes_NNP differentially_RB expressed_VBD in_IN the_DT M_NNP ._. F_NN ._. responding_VBG
        lesion_NN after_IN 1_CD and_CC four_CD doses_NNS of_IN IL-_NNP 2_CD
        Genes_NNP differentially_RB expressed_VBD in_IN the_DT M_NNP ._. F_NN ._. responding_VBG
        lesion_NN after_IN 1_CD and_CC four_CD doses_NNS of_IN IL-_NNP 2_CD
        Click_NNP here_RB for_IN additional_JJ data_NNS file_VBP
      
    
  
